Dr. Alaina Vidmar, M.D

NPI: 1619242807
Total Payments
$17,889
2024 Payments
$3,091
Companies
3
Transactions
12

Payment Breakdown by Category

Other$9,825 (54.9%)
Consulting$7,725 (43.2%)
Food & Beverage$208.78 (1.2%)
Education$130.45 (0.7%)

Payments by Nature

Nature of Payment Amount Transactions Share
Honoraria $9,825 4 54.9%
Consulting Fee $7,725 3 43.2%
Food and Beverage $208.78 2 1.2%
Education $130.45 3 0.7%

Top Paying Companies

Company Total Records Latest Year
Rhythm Pharmaceuticals, Inc. $17,828 10 $0 (2024)
PFIZER INC. $39.95 1 $0 (2017)
Novo Nordisk Inc $21.28 1 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2024 $3,091 3 Rhythm Pharmaceuticals, Inc. ($3,091)
2023 $12,113 6 Rhythm Pharmaceuticals, Inc. ($12,113)
2022 $2,625 1 Rhythm Pharmaceuticals, Inc. ($2,625)
2018 $21.28 1 Novo Nordisk Inc ($21.28)
2017 $39.95 1 PFIZER INC. ($39.95)

All Payment Transactions

12 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
05/16/2024 Rhythm Pharmaceuticals, Inc. Education In-kind items and services $59.50 General
05/16/2024 Rhythm Pharmaceuticals, Inc. Education In-kind items and services $31.00 General
01/12/2024 Rhythm Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $3,000.00 General
12/01/2023 Rhythm Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $1,125.00 General
11/10/2023 Rhythm Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $3,600.00 General
10/15/2023 Rhythm Pharmaceuticals, Inc. Honoraria Cash or cash equivalent $1,125.00 General
10/14/2023 Rhythm Pharmaceuticals, Inc. Honoraria Cash or cash equivalent $3,600.00 General
10/14/2023 Rhythm Pharmaceuticals, Inc. Food and Beverage In-kind items and services $187.50 General
06/28/2023 Rhythm Pharmaceuticals, Inc. Imcivree (Drug) Honoraria Cash or cash equivalent $2,475.00 General
Category: Genetic Disease
11/01/2022 Rhythm Pharmaceuticals, Inc. Imcivree (Drug) Honoraria Cash or cash equivalent $2,625.00 General
Category: Genetic Disease
03/18/2018 Novo Nordisk Inc Victoza (Drug) Food and Beverage In-kind items and services $21.28 General
Category: Diabetes
03/28/2017 PFIZER INC. GENOTROPIN (Drug) Education In-kind items and services $39.95 General
Category: ENDOCRINE DISEASE

About Dr. Alaina Vidmar, M.D

Dr. Alaina Vidmar, M.D is a Pediatric Endocrinology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/20/2012. The National Provider Identifier (NPI) number assigned to this provider is 1619242807.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alaina Vidmar, M.D has received a total of $17,889 in payments from pharmaceutical and medical device companies, with $3,091 received in 2024. These payments were reported across 12 transactions from 3 companies. The most common payment nature is "Honoraria" ($9,825).

Practice Information

  • Specialty Pediatric Endocrinology
  • Location Los Angeles, CA
  • Active Since 03/20/2012
  • Last Updated 01/04/2017
  • Taxonomy Code 2080P0205X
  • Entity Type Individual
  • NPI Number 1619242807

Products in Payments

  • Imcivree (Drug) $5,100
  • GENOTROPIN (Drug) $39.95
  • Victoza (Drug) $21.28

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Endocrinology Doctors in Los Angeles